These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 21539681)

  • 1. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker.
    Takawa M; Masuda K; Kunizaki M; Daigo Y; Takagi K; Iwai Y; Cho HS; Toyokawa G; Yamane Y; Maejima K; Field HI; Kobayashi T; Akasu T; Sugiyama M; Tsuchiya E; Atomi Y; Ponder BA; Nakamura Y; Hamamoto R
    Cancer Sci; 2011 Jul; 102(7):1298-305. PubMed ID: 21539681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer.
    Huqun ; Ishikawa R; Zhang J; Miyazawa H; Goto Y; Shimizu Y; Hagiwara K; Koyama N
    Cancer; 2012 Mar; 118(6):1599-606. PubMed ID: 21837672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.
    Zhang JG; Guo JF; Liu DL; Liu Q; Wang JJ
    J Thorac Oncol; 2011 Apr; 6(4):671-8. PubMed ID: 21270667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
    Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
    Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and metastasis in gastric cancer.
    Choi JH; Song YS; Yoon JS; Song KW; Lee YY
    APMIS; 2010 Mar; 118(3):196-202. PubMed ID: 20132185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased expression of EZH2, a polycomb group protein, in bladder carcinoma.
    Arisan S; Buyuktuncer ED; Palavan-Unsal N; Caşkurlu T; Cakir OO; Ergenekon E
    Urol Int; 2005; 75(3):252-7. PubMed ID: 16215315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma.
    Behrens C; Solis LM; Lin H; Yuan P; Tang X; Kadara H; Riquelme E; Galindo H; Moran CA; Kalhor N; Swisher SG; Simon GR; Stewart DJ; Lee JJ; Wistuba II
    Clin Cancer Res; 2013 Dec; 19(23):6556-65. PubMed ID: 24097870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer.
    Cao W; Ribeiro Rde O; Liu D; Saintigny P; Xia R; Xue Y; Lin R; Mao L; Ren H
    PLoS One; 2012; 7(12):e52984. PubMed ID: 23300840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The expression and significance of the enhancer of zeste homolog 2 in lung adenocarcinoma.
    Lv Y; Yuan C; Xiao X; Wang X; Ji X; Yu H; Wu Z; Zhang J
    Oncol Rep; 2012 Jul; 28(1):147-54. PubMed ID: 22552406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minichromosome Maintenance Protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancer.
    Toyokawa G; Masuda K; Daigo Y; Cho HS; Yoshimatsu M; Takawa M; Hayami S; Maejima K; Chino M; Field HI; Neal DE; Tsuchiya E; Ponder BA; Maehara Y; Nakamura Y; Hamamoto R
    Mol Cancer; 2011 May; 10():65. PubMed ID: 21619671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The knock-down of overexpressed EZH2 and BMI-1 does not prevent osteosarcoma growth.
    Sasaki H; Setoguchi T; Matsunoshita Y; Gao H; Hirotsu M; Komiya S
    Oncol Rep; 2010 Mar; 23(3):677-84. PubMed ID: 20127006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression profile of the polycomb group protein enhancer of Zeste homologue 2 and its prognostic relevance in renal cell carcinoma.
    Hinz S; Weikert S; Magheli A; Hoffmann M; Engers R; Miller K; Kempkensteffen C
    J Urol; 2009 Dec; 182(6):2920-5. PubMed ID: 19846140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. linc01088 promotes cell proliferation by scaffolding EZH2 and repressing p21 in human non-small cell lung cancer.
    Liu JQ; Feng YH; Zeng S; Zhong MZ
    Life Sci; 2020 Jan; 241():117134. PubMed ID: 31811854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells.
    Sakurai T; Bilim VN; Ugolkov AV; Yuuki K; Tsukigi M; Motoyama T; Tomita Y
    Biochem Biophys Res Commun; 2012 Jun; 422(4):607-14. PubMed ID: 22609199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of EZH2 expression in patients with oesophageal cancer: a meta-analysis.
    Wang Y; Gao F; Zhao M; Li B; Xing D; Wang J; Yang Y
    J Cell Mol Med; 2016 May; 20(5):836-41. PubMed ID: 26859127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder.
    Raman JD; Mongan NP; Tickoo SK; Boorjian SA; Scherr DS; Gudas LJ
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8570-6. PubMed ID: 16361539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancer of zeste homolog 2 overexpression in nasopharyngeal carcinoma: an independent poor prognosticator that enhances cell growth.
    Hwang CF; Huang HY; Chen CH; Chien CY; Hsu YC; Li CF; Fang FM
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):597-604. PubMed ID: 21300475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer.
    Ding M; Zhang H; Li Z; Wang C; Chen J; Shi L; Xu D; Gao Y
    Clin Exp Pharmacol Physiol; 2015 May; 42(5):458-64. PubMed ID: 25739318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polycomb repressor complex-2 is a novel target for mesothelioma therapy.
    Kemp CD; Rao M; Xi S; Inchauste S; Mani H; Fetsch P; Filie A; Zhang M; Hong JA; Walker RL; Zhu YJ; Ripley RT; Mathur A; Liu F; Yang M; Meltzer PA; Marquez VE; De Rienzo A; Bueno R; Schrump DS
    Clin Cancer Res; 2012 Jan; 18(1):77-90. PubMed ID: 22028491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2.
    Ougolkov AV; Bilim VN; Billadeau DD
    Clin Cancer Res; 2008 Nov; 14(21):6790-6. PubMed ID: 18980972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.